Articles: Volume 22.04 October-December 2018

GLAD to study genetic links in anxiety and depression

A major new study aims to recruit 40 000 people, who will sign up online to take part in trailblazing research into the genetic links to anxiety and depression.
Read the full article.

More details...

Genetic investigation in dementia: new interpretive challenges

Genetic testing is increasingly used in the assessment and investigation of individuals with dementia and cognitive impairment. Next generation sequencing dementia panels allow simultaneous parallel examination of multiple genes. But with this increased diagnostic power comes also the possibility of incidental findings, of identifying sequence …

More details...

Eye drop psychosis in Parkinson’s disease: a cautionary tale

Anticholinergic agents are used in a number of conditions ranging from overactive bladder and bradycardia to travel sickness but side-effects such as hallucinations, impaired memory and restlessness are increasingly recognised, though still underreported in clinical practice. In Parkinson’s disease anticholinergics such as atropine are recommended …

More details...

A case for adding fluvoxamine to clozapine

Treatment-refractory schizophrenia affects at least 30% of all patients with schizophrenia. Clozapine remains the gold standard treatment as the chances of response with another non clozapine medication are very low. However, initiating and then maintaining patients on clozapine can be a challenge due to a …

More details...

Rapidly progressive dementia with psychosis caused by CJD

Rapidly progressive dementias are conditions that typically cause dementia over weeks or months. They are a particular challenge for psychiatrists and neurologists as the differential diagnosis is often different from the more typical, slowly progressive dementias. Early and accurate diagnosis is essential, as many of …

More details...

Letter: eponyms revisited

Some years ago I published a paper in the journal on dementia diagnosis which examined the use of an overlapping figure test of visuoperceptual function, a figure originally described in 1917 by the German neuropsychiatrist Walter Poppelreuter (1886-1939) and hence known as the “Poppelreuter figure”.
At …

More details...

Screening for depression in patients with cognitive impairment: a local audit

Depression is highly prevalent in cognitive impairment and is considered one of the most common comorbid conditions in dementia.1 Despite this, underlying depressive symptoms can easily be missed2 by health care providers, mainly due to lack of awareness and lack of routine screening for depressive …

More details...

Cognitive screeners for MCI: is correction of skewed data necessary?

Correct identification of mild cognitive impairment (MCI) may provide the opportunity for intervention with diseasemodifying therapeutics. Pending the development of widely applicable diagnostic biomarkers, use of cognitive screening instruments (CSIs) as part of clinical assessment may represent the best method for early MCI diagnosis. However, …

More details...

Beta-amyloid PET imaging for Alzheimer’s dementia diagnosis

Alzheimer’s dementia is the most commonly diagnosed dementia. Despite this, diagnosis can be especially complex in certain circumstances. Any additional, novel diagnostic aids can positively add to the diagnostic process, overall accuracy and ultimately to patient care and treatment. Beta-amyloid (Aß) positron emission tomography (PET) …

More details...

Web design and marketing agency Leamington Spa